David Hutton

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.

This intellectual property protects Kiora's pipeline by covering several inflammatory-related therapeutic applications, including posterior non-infectious uveitis.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Megan Baldwin, PhD, CEO and managing director of Opthea Limited, spoke with our team about the company's clinical trial drug OPT-302 (sozinibercept) at the 2023 ASRS annual meeting.

An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.

At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.

At the 2023 ASRS annual meeting, Aleksandra Rachiskaya, MD, spoke about time to fluid control with faricimab arms complete compared to aflibercept in recent studies.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.

Durga Borkar, MD, MMCi, discussed the FARETINA-DME study during the 2023 ASRS meeting in Seattle, Washington.

Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.

Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

Michael Ip, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why they're vital to a modern view of ophthalmology.

Diana Do, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington, to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

Carl Danzig, MD, shared the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS meeting.

At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, shared how new techniques are expanding the options for deep learning in ophthalmology.

Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.

Jennifer I. Lim, MD, FARVO, FASRS shares insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis."

Our team caught up with Baruch Kupperman, MD, PhD to learn about his ASRS presentation, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease."

The company announced it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.

According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.

Orbis International physician spotlights the latest trends for cataract surgery training.

According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

Nicholas Volpe, MD shares insights from his talk titled "Optic Neuropathy Versus Maculopathy" at the European Society of Ophthalmology Congress being held in Prague.

Dr Christiana Dinah discusses her SOE presentation, "Geographic Atrophy: A Mixed Method Study."

Scientists hope to develop novel AI solutions for the prediction of DPN using corneal OCT images.

According to Bausch + Lomb and Novaliq, MIEBO is the first prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.